Tests a herbal and conventional treatment plan for Sjögren's gland damage
Compares an optimized Chinese and Western medicine plan with usual care in primary Sjögren's syndrome.
Plain-language title generated from the registry record
Registry title: Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary Sjögren's syndrome and a qi and yin deficiency (a traditional Chinese medicine pattern). It tests a combined Chinese and Western medicine program for damage to the glands.
- Age
- 18 Years to 75 Years
- Sex
- Women and men can join.
- Disease stage
- Primary Sjögren's syndrome (pSS) with qi and yin deficiency. Active damage to body systems (ESSDAI score ≥5) is not allowed.
Main reasons for not taking part
- pSS active system damage (ESSDAI score ≥5)
- Other connective tissue diseases besides pSS
- Pregnant or breastfeeding women
- Severe heart or brain blood vessel disease, liver or kidney failure, or severe cancer
- Taking psychotropic drugs
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06519617, who can take part
Where in China
- China-Japan Friendship HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qingwen Tao
- Trial code
- NCT06519617
- Record updated
- 25 July 2024
- Original description
ChatGPT In a randomized controlled trial, 136 patients with primary Sjögren's syndrome (pSS) meeting the inclusion criteria were enrolled and randomly divided into two groups of 68 each. The treatment group received an optimized program combining Chinese and Western medicine for pSS glandular injury, while the control group received a conventional program for pSS glandular damage. The primary efficacy endpoint was the 12-week non-stimulated salivary flow rate (UWS) score. Secondary efficacy endpoints included the glandular damage Visual Analog Scale (VAS) scores, the European Sjögren's Syndrome Patient Reported Index (ESSPRI), among others. The treatment course lasted 12 weeks. The efficacy and safety of the optimized program for pSS glandular injury were evaluated by comparing within and between groups before and after treatment.Read full original descriptionShow less
Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for Primary Sjogren's Syndrome Glandular Damage
ChatGPT In a randomized controlled trial, 136 patients with primary Sjögren's syndrome (pSS) meeting the inclusion criteria were enrolled and randomly divided into two groups of 68 each. The treatment group received an optimized program combining Chinese and Western medicine for pSS glandular injury, while the control group received a conventional program for pSS glandular damage. The primary efficacy endpoint was the 12-week non-stimulated salivary flow rate (UWS) score. Secondary efficacy endpoints included the glandular damage Visual Analog Scale (VAS) scores, the European Sjögren's Syndrome Patient Reported Index (ESSPRI), among others. The treatment course lasted 12 weeks. The efficacy and safety of the optimized program for pSS glandular injury were evaluated by comparing within and between groups before and after treatment.
Inclusion: 1. clinical diagnosis of pSS and qi and yin deficiency ; 2.Sign the informed consent form.
Exclusion: 1. pSS activity system damage (ESSDAI score ≥5); 2. Combined connective tissue diseases other than pSS; 3. Pregnant or lactating women; 4. severe cardiovascular and cerebrovascular diseases, liver and kidney failure, and severe malignant tumors; 5. taking psychotropic drugs; 6. assessed by the investigator to be ineligible for enrollment.